Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2024 | Inspiring advances in research through scientific meetings

Manfred Windisch • 6 Mar 2024
AD/PD 2024
Alzheimer’s Disease Dementia

As Executive Organizer of AD/PD™, Manfred Windisch, PhD, NeuroScios GmbH, Graz, Austria, discusses the importance of the conference in inspiring advances for Alzheimer’s disease. He highlights the growth of the conference, and its aim to attract more young scientists and clinicians, with more than 40% of scientists in attendance below the age of 40. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Manfred Windisch

The direction of disease-modifying therapeutic development in Alzheimer’s disease 1:46
The direction of disease-modifying therapeutic development in Alzheimer’s disease
Manfred Windisch • 6 Mar 2024
The challenges of using animal models in Alzheimer’s research 1:36
The challenges of using animal models in Alzheimer’s research
Manfred Windisch • 6 Mar 2024
Updates in Alzheimer’s treatment: the potential of NSC001 4:12
Updates in Alzheimer’s treatment: the potential of NSC001
Manfred Windisch • 6 Mar 2024

Related Videos

Gut microbiome as a risk stratification tool and prevention target for neurodegenerative diseases 3:54
Gut microbiome as a risk stratification tool and prevention target for neurodegenerative diseases
Muhaison Ibrahim • 10 Dec 2025
Microbiome-brain volume associations in cognitively unimpaired adults enriched for AD risk 6:35
Microbiome-brain volume associations in cognitively unimpaired adults enriched for AD risk
Muhaison Ibrahim • 10 Dec 2025
Shingles vaccination is associated with a reduced risk of new dementia diagnoses 4:49
Shingles vaccination is associated with a reduced risk of new dementia diagnoses
Pascal Geldsetzer • 8 Dec 2025
The potential of plasma biomarkers in assessing preclinical Alzheimer’s disease 3:25
The potential of plasma biomarkers in assessing preclinical Alzheimer’s disease
Gemma Salvadó • 12 Dec 2025
The content of VJDementia is intended for healthcare professionals